Transglutaminases in disease

Transglutaminases (TGases) are enzymes that are widely used in many biological systems for generic tissue stabilization purposes. Mutations resulting in lost activity underlie several serious disorders. In addition, new evidence documents that they may also be aberrantly activated in tissues and cells and contribute to a variety of diseases, including neurodegenerative diseases such as Alzheimer's and Huntington's diseases. In these cases, the TGases appear to be a factor in the formation of inappropriate proteinaceous aggregates that may be cytotoxic. In other cases such as celiac disease, however, TGases are involved in the generation of autoantibodies. Further, in diseases such as progressive supranuclear palsy, Huntington's, Alzheimer's and Parkinson's diseases, the aberrant activation of TGases may be caused by oxidative stress and inflammation. This review will examine the role and activation of TGases in a variety of diseases.

[1]  E. Thorsby,et al.  Binding of peptides from the N-terminal region of alpha-gliadin to the celiac disease-associated HLA-DQ2 molecule assessed in biochemical and T cell assays. , 1996, Clinical immunology and immunopathology.

[2]  W. Martin,et al.  Cortical glucose metabolism in Huntington's disease , 1992, Neurology.

[3]  W. Engel,et al.  β‐Amyloid precursor epitopes in muscle fibers of inclusion body myositis , 1993 .

[4]  R. Baker,et al.  Mutations causing coagulation factor XIII subunit A deficiency: characterization of the mutant proteins after expression in yeast. , 1995, Blood.

[5]  S. W. Davies,et al.  Exon 1 of the HD Gene with an Expanded CAG Repeat Is Sufficient to Cause a Progressive Neurological Phenotype in Transgenic Mice , 1996, Cell.

[6]  T. Reunala,et al.  Diseases associated with dermatitis herpetiformis , 1997, The British journal of dermatology.

[7]  J. Bowness,et al.  Increased transglutaminase in the aortas of cholesterol-fed rabbits: occurrence of buffer soluble and insoluble forms and an inhibitor. , 1991, Biochemistry and cell biology = Biochimie et biologie cellulaire.

[8]  Steven Finkbeiner,et al.  Huntingtin Acts in the Nucleus to Induce Apoptosis but Death Does Not Correlate with the Formation of Intranuclear Inclusions , 1998, Cell.

[9]  A. Mukherjee,et al.  Transglutaminase-catalyzed incorporation of polyamines into phospholipase A2. , 1993, Journal of biochemistry.

[10]  C. Bodemer,et al.  Three Novel Point Mutations in the Keratinocyte Transglutaminase (TGK) Gene in Lamellar Ichthyosis: Significance for Mutant Transcript Level, TGK Immunodetection and Activity , 1997, European journal of human genetics : EJHG.

[11]  H. Green.  Human genetic diseases due to codon reiteration: Relationship to an evolutionary mechanism , 1993, Cell.

[12]  W. Stolz,et al.  Bullous pemphigoid of childhood: autoantibodies target the same epitopes within the NC16A domain of BP180 as autoantibodies in bullous pemphigoid of adulthood. , 2000, Archives of dermatology.

[13]  L. Lorand,et al.  Formation of a 55,000 molecular-weight crosslinked .beta. crystallin dimer in the calcium treated lens. A model for cataract , 1985 .

[14]  D. Schuppan,et al.  Antibodies to tissue transglutaminase as serologic markers in patients with dermatitis herpetiformis. , 1999, The Journal of investigative dermatology.

[15]  H. Green,et al.  Peptides containing glutamine repeats as substrates for transglutaminase-catalyzed cross-linking: relevance to diseases of the nervous system. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  R. Timpl,et al.  Identification of a substrate site for liver transglutaminase on the aminopropeptide of type III collagen. , 1987, The Journal of biological chemistry.

[17]  R. Willette,et al.  Factor XIIIa cross-links lipoprotein(a) with fibrinogen and is present in human atherosclerotic lesions. , 1998, Circulation research.

[18]  S. Hersch,et al.  Huntingtin aggregates may not predict neuronal death in Huntington's disease , 1999 .

[19]  S. Dudek,et al.  Transglutaminase facilitates the formation of polymers of the β-amyloid peptide , 1994, Brain Research.

[20]  L. Sporn,et al.  Thrombin cleavage-independent deposition of fibrinogen in extracellular matrices. , 1997, Blood.

[21]  M. Raghunath,et al.  Cross-linking of the dermo-epidermal junction of skin regenerating from keratinocyte autografts. Anchoring fibrils are a target for tissue transglutaminase. , 1996, The Journal of clinical investigation.

[22]  S. Bale,et al.  Congenital recessive ichthyosis unlinked to loci for epidermal transglutaminases. , 1996, The Journal of investigative dermatology.

[23]  T. Bayer,et al.  Lewy body variant of Alzheimer's disease: α‐synuclein in dystrophic neurites of Aβ plaques , 2000 .

[24]  S. W. Davies,et al.  Intranuclear Neuronal Inclusions in Huntington's Disease and Dentatorubral and Pallidoluysian Atrophy: Correlation between the Density of Inclusions andIT15CAG Triplet Repeat Length , 1998, Neurobiology of Disease.

[25]  J. Weinberg,et al.  Extravascular fibrin formation and dissolution in synovial tissue of patients with osteoarthritis and rheumatoid arthritis. , 1991, Arthritis and rheumatism.

[26]  J. Stankova,et al.  IL-10 Up-Regulates CCR5 Gene Expression in Human Monocytes , 1999, Inflammation.

[27]  D. Aeschlimann,et al.  Protein Crosslinking in Assembly and Remodelling of Extracellular Matrices: The Role of Transglutaminases , 2000, Connective tissue research.

[28]  T. Tamaki,et al.  Cross-linking of α2-plasmin inhibitor and fibronectin to fibrin by fibrin-stabilizing factor , 1981 .

[29]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[30]  F. Koning,et al.  Selective deamidation by tissue transglutaminase strongly enhances gliadin-specific T cell reactivity. , 1998, Journal of immunology.

[31]  A. Engel,et al.  Analysis of cytokine expression in muscle in inflammatory myopathies, Duchenne dystrophy, and non-weak controls , 1995, Journal of Neuroimmunology.

[32]  Y. Agid,et al.  Screening for proteins with polyglutamine expansions in autosomal dominant cerebellar ataxias. , 1996, Human molecular genetics.

[33]  L. Lorand,et al.  Novel inhibitors against the transglutaminase-catalysed crosslinking of lens proteins. , 1998, Experimental eye research.

[34]  J. Bach,et al.  Insulin-dependent diabetes mellitus as an autoimmune disease. , 1994, Endocrine reviews.

[35]  J. Blass,et al.  The α-ketoglutarate dehydrogenase complex in neurodegeneration , 2000, Neurochemistry International.

[36]  M. MacDonald,et al.  Molecular genetics of Huntington's disease. , 1993, Results and problems in cell differentiation.

[37]  F. Rodeghiero,et al.  Molecular mechanisms of type II factor XIII deficiency: novel Gly562-Arg mutation and C-terminal truncation of the A subunit cause factor XIII deficiency as characterized in a mammalian expression system. , 1998, Blood.

[38]  R. Ádány,et al.  Identification of Cytoplasmic Actin as an Abundant Glutaminyl Substrate for Tissue Transglutaminase in HL-60 and U937 Cells Undergoing Apoptosis* , 1997, The Journal of Biological Chemistry.

[39]  M. Paulsson,et al.  Transglutaminase-catalyzed matrix cross-linking in differentiating cartilage: identification of osteonectin as a major glutaminyl substrate , 1995, The Journal of cell biology.

[40]  P. Reitsma,et al.  A Genetic Propensity to High Factor VII Is not Associated with the Risk of Myocardial Infarction in Men , 1998 .

[41]  S. W. Davies,et al.  Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. , 1997, Science.

[42]  T. L. Moser,et al.  Vitronectin is a substrate for transglutaminases. , 1988, Biochemical and biophysical research communications.

[43]  G. Gilad,et al.  Transglutaminase Activity in Rat Brain: Characterization, Distribution, and Changes with Age , 1985, Journal of neurochemistry.

[44]  F. Hucho,et al.  Ca2+‐dependent inactivation of acetylcholine receptors by an endogenous transglutaminase , 1986, FEBS letters.

[45]  P. Steinert,et al.  Biochemical Evidence That Small Proline-rich Proteins and Trichohyalin Function in Epithelia by Modulation of the Biomechanical Properties of Their Cornified Cell Envelopes* , 1998, The Journal of Biological Chemistry.

[46]  M. Beal,et al.  Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[47]  F. Boscia,et al.  Protein oxidation and lens opacity in humans. , 2000, Investigative ophthalmology & visual science.

[48]  Soo-Youl Kim,et al.  Differential Expression of Multiple Transglutaminases in Human Brain , 1999, The Journal of Biological Chemistry.

[49]  S. Auricchio,et al.  Cereal dietary proteins with sites for cross-linking by transglutaminase , 1990 .

[50]  C. Masters,et al.  Amyloid plaque core protein in Alzheimer disease and Down syndrome. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[51]  J. Blass,et al.  A sensitive fluorometric assay for tissue transglutaminase. , 2001, Analytical biochemistry.

[52]  N. Cairns,et al.  Tau proteins of alzheimer paired helical filaments: Abnormal phosphorylation of all six brain isoforms , 1992, Neuron.

[53]  L. Lorand,et al.  Cross‐Linking Sites of the Human Tau Protein, Probed by Reactions with Human Transglutaminase , 1998, Journal of neurochemistry.

[54]  K. Ikai,et al.  The presence of autoantibody to lipocortin-I in autoimmune-prone MRL mice. , 1992, Autoimmunity.

[55]  R. Hennekam,et al.  Clinical, serologic, and immunogenetic features of familial idiopathic inflammatory myopathy. , 1998, Arthritis and rheumatism.

[56]  E. Havrdová,et al.  Occurrence of IgA and IgG autoantibodies to calreticulin in coeliac disease and various autoimmune diseases. , 2000, Journal of autoimmunity.

[57]  D. Selkoe,et al.  Brain transglutaminase: in vitro crosslinking of human neurofilament proteins into insoluble polymers. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[58]  P. Højrup,et al.  Localization of transglutaminase-reactive glutamine residues in bovine osteopontin. , 1994, The Biochemical journal.

[59]  J. Finlayson,et al.  The ɛ-(γ-Glutamyl)Lysine Crosslink and the Catalytic Role of Transglutaminases , 1977 .

[60]  J. Blass,et al.  Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. , 1998, Archives of biochemistry and biophysics.

[61]  K. Fujikawa,et al.  Amino acid sequence of the b subunit of human factor XIII, a protein composed of ten repetitive segments. , 1986, Biochemistry.

[62]  Claire-Anne Gutekunst,et al.  Nuclear and Neuropil Aggregates in Huntington’s Disease: Relationship to Neuropathology , 1999, The Journal of Neuroscience.

[63]  G. Duncan,et al.  A human lens model of cortical cataract: Ca2+-induced protein loss, vimentin cleavage and opacification. , 2000, Investigative ophthalmology & visual science.

[64]  William B. Dobyns,et al.  Autosomal dominant cerebellar ataxia (SCA6) associated with small polyglutamine expansions in the α1A-voltage-dependent calcium channel , 1997, Nature Genetics.

[65]  J. Bowness,et al.  Transglutaminase-catalysed cross-linking: a potential mechanism for the interaction of fibrinogen, low density lipoprotein and arterial type III procollagen. , 1989, Thrombosis research.

[66]  K. Lundin,et al.  Gluten induces an intestinal cytokine response strongly dominated by interferon gamma in patients with celiac disease. , 1998, Gastroenterology.

[67]  Y. Agid,et al.  Cloning of the SCA7 gene reveals a highly unstable CAG repeat expansion , 1997, Nature Genetics.

[68]  K. Fujikawa,et al.  Amino acid sequence of the a subunit of human factor XIII. , 1986, Biochemistry.

[69]  D. Schuppan,et al.  Identification of tissue transglutaminase as the autoantigen of celiac disease , 1997, Nature Medicine.

[70]  K. Wuepper,et al.  Keratin cross-linking and epidermal transglutaminase. A review with observations on the histochemical and immunochemical localization of the enzyme. , 1975, The Journal of investigative dermatology.

[71]  W. D. de Jong,et al.  Exposure of beta H-crystallin to hydroxyl radicals enhances the transglutaminase-susceptibility of its existing amine-donor and amine-acceptor sites. , 1993, The Biochemical journal.

[72]  G. Melino,et al.  Gene Disruption of Tissue Transglutaminase , 2001, Molecular and Cellular Biology.

[73]  M. H. Polymeropoulos,et al.  Alpha synuclein in neurodegenerative disorders: Murderer or accomplice? , 1998, Nature Medicine.

[74]  R. Powers,et al.  Transglutaminase activity is increased in Alzheimer's disease brain , 1997, Brain Research.

[75]  R. Ferrante,et al.  Tissue Transglutaminase Is Increased in Huntington's Disease Brain , 1999, Journal of neurochemistry.

[76]  J. Bach,et al.  Evidence for an antigen-driven selection process in human autoantibodies against acetylcholine receptor. , 1995, Molecular immunology.

[77]  C. Barnes,et al.  The neurochemical and behavioral effects of β-amyloid peptide(25–35) , 1996, Brain Research.

[78]  R. Sasaki,et al.  Cross‐linking of a synthetic partial‐length (1–28) peptide of the Alzheimer β/A4 amyloid protein by transglutaminase , 1993, FEBS letters.

[79]  P. Roepstorff,et al.  The Intestinal T Cell Response to α-Gliadin in Adult Celiac Disease Is Focused on a Single Deamidated Glutamine Targeted by Tissue Transglutaminase , 2000, The Journal of experimental medicine.

[80]  Kazuhito Ogawa,et al.  Transglutaminase activity in serum and cerebrospinal fluid in sporadic amyotrophic lateral sclerosis: A possible use as an indicator of extent of the motor neuron loss , 1998, Journal of the Neurological Sciences.

[81]  R. Timpl,et al.  Two Adjacent N-terminal Glutamines of BM-40 (Osteonectin, SPARC) Act as Amine Acceptor Sites in TransglutaminaseC-catalyzed Modification (*) , 1995, The Journal of Biological Chemistry.

[82]  L. K. Rasmussen,et al.  Residues in the synuclein consensus motif of the alpha-synuclein fragment, NAC, participate in transglutaminase-catalysed cross-linking to Alzheimer-disease amyloid beta A4 peptide. , 1995, The Biochemical journal.

[83]  F. Leblhuber,et al.  Activated Immune System in Patients with Huntington's Disease , 1998, Clinical Chemistry and Laboratory Medicine.

[84]  K. Fischbeck,et al.  Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.

[85]  D. Mosher.  Cross-linking of fibronectin to collagenous proteins , 2004, Molecular and Cellular Biochemistry.

[86]  J. Weissenbach,et al.  Two new loci for autosomal recessive ichthyosis on chromosomes 3p21 and 19p12-q12 and evidence for further genetic heterogeneity. , 2000, American journal of human genetics.

[87]  M. Paulsson,et al.  Transglutaminases: Protein Cross-Linking Enzymes in Tissues and Body Fluids , 1994, Thrombosis and Haemostasis.

[88]  J. Goldman,et al.  Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[89]  V. Chang,et al.  Lipoprotein (a) is a substrate for factor XIIIa and tissue transglutaminase. , 1991, The Journal of biological chemistry.

[90]  H. Coppin,et al.  Human collagen II peptide 256–271 preferentially binds to HLA-DR molecules associated with susceptibility to rheumatoid arthritis , 1999, Immunogenetics.

[91]  A. Roses,et al.  Polyglutamine Domains Are Substrates of Tissue Transglutaminase: Does Transglutaminase Play a Role in Expanded CAG/Poly‐Q Neurodegenerative Diseases? , 1997, Journal of neurochemistry.

[92]  R. Krüger,et al.  Genetic dissection of familial Parkinson's disease. , 1998, Molecular medicine today.

[93]  E. Riecken,et al.  Identification of the Autoantigen of Celiac Disease , 1998, Annals of the New York Academy of Sciences.

[94]  A. Delacourte,et al.  Abnormal Tau proteins in progressive supranuclear palsy , 1991, Acta Neuropathologica.

[95]  P M Steinert,et al.  Sporadic Inclusion Body Myositis Correlates with Increased Expression and Cross-linking by Transglutaminases 1 and 2* , 2000, The Journal of Biological Chemistry.

[96]  J. Sjöstrand,et al.  Calcium-Dependent Proteolysis in Rabbit Lens Epithelium after Oxidative Stress , 1998, Ophthalmic Research.

[97]  D. Selkoe,et al.  Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[98]  Huda Y. Zoghbi,et al.  Expansion of an unstable trinucleotide CAG repeat in spinocerebellar ataxia type 1 , 1993, Nature Genetics.

[99]  H. Goebel,et al.  Juvenile Huntington chorea , 1978, Neurology.

[100]  P. Steinert,et al.  Initiation of assembly of the cell envelope barrier structure of stratified squamous epithelia. , 1999, Molecular biology of the cell.

[101]  M. Piacentini,et al.  Identification of ‘tissue’ transglutaminase binding proteins in neural cells committed to apoptosis , 1999, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[102]  Hans Lassmann,et al.  Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ , 2004, Acta Neuropathologica.

[103]  C. W. Prince,et al.  Osteopontin, a substrate for transglutaminase and factor XIII activity. , 1991, Biochemical and biophysical research communications.

[104]  S. Carpenter.  Inclusion Body Myositis, a Review , 1996, Journal of neuropathology and experimental neurology.

[105]  M. Beal,et al.  Oxidative damage and metabolic dysfunction in Huntington's disease: Selective vulnerability of the basal ganglia , 1997, Annals of neurology.

[106]  C. Gohr,et al.  Participation of transglutaminase in the activation of latent transforming growth factor beta1 in aging articular cartilage. , 2000, Arthritis and rheumatism.

[107]  E. Brouillet,et al.  Effects of chronic MPTP and 3-nitropropionic acid in nonhuman primates. , 1995, Current opinion in neurology.

[108]  Georg Auburger,et al.  Moderate expansion of a normally biallelic trinucleotide repeat in spinocerebellar ataxia type 2 , 1996, Nature Genetics.

[109]  F. Di Lisa,et al.  Transglutaminase-catalyzed polymerization of troponin in vitro. , 1995, Biochemical and biophysical research communications.

[110]  F. Schmitt,et al.  Alzheimer neuropathologic alterations in aged cognitively normal subjects. , 1999, Journal of neuropathology and experimental neurology.

[111]  G. Johnson,et al.  Transglutaminase Cross‐Linking of the τ Protein , 1995 .

[112]  P. Steinert,et al.  Bricks and mortar of the epidermal barrier , 1999, Experimental & Molecular Medicine.

[113]  M. Mosesson,et al.  Cross-linking of Plasminogen Activator Inhibitor 2 and α2-Antiplasmin to Fibrin(ogen)* , 2000, The Journal of Biological Chemistry.

[114]  C A Ross,et al.  Correlation between the onset age of Huntington's disease and length of the trinucleotide repeat in IT-15. , 1993, Human molecular genetics.

[115]  M. Dalakas,et al.  HLA allele distribution distinguishes sporadic inclusion body myositis from hereditary inclusion body myopathies , 1998, Journal of Neuroimmunology.

[116]  J. Kleman,et al.  Transglutaminase-catalyzed cross-linking of fibrils of collagen V/XI in A204 rhabdomyosarcoma cells. , 1995, Biochemistry.

[117]  R. Doolittle,et al.  Amino acid sequence studies on the alpha chain of human fibrinogen. Exact location of cross-linking acceptor sites. , 1979, Biochemistry.

[118]  R. Doolittle,et al.  - cross-linking sites in human and bovine fibrin. , 1971, Biochemistry.

[119]  S. Dudek,et al.  Transglutaminase Catalyzes the Formation of Sodium Dodecyl Sulfate‐Insoluble, Alz‐50‐Reactive Polymers of τ , 1993, Journal of neurochemistry.

[120]  J. Weissenbach,et al.  Mapping of a second locus for lamellar ichthyosis to chromosome 2q33-35. , 1996, Human molecular genetics.

[121]  A. Roses,et al.  Transglutaminase-catalyzed inactivation of glyceraldehyde 3-phosphate dehydrogenase and alpha-ketoglutarate dehydrogenase complex by polyglutamine domains of pathological length. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[122]  G. Sobue,et al.  Differential pattern in tissue-specific somatic mosaicism of expanded CAG trinucleotide repeat in dentatorubral-pallidoluysian atrophy, Machado-Joseph disease, and X-linked recessive spinal and bulbar muscular atrophy , 1996, Journal of the Neurological Sciences.

[123]  R. Kannagi,et al.  Calcium-induced intracellular cross-linking of lipocortin I by tissue transglutaminase in A431 cells. Augmentation by membrane phospholipids. , 1991, The Journal of biological chemistry.

[124]  G. Corrao,et al.  Serological screening of coeliac disease: choosing the optimal procedure according to various prevalence values. , 1994, Gut.

[125]  P. Steinert.  The Complexity and Redundancy of Epithelial Barrier Function , 2000, The Journal of cell biology.

[126]  Manish S. Shah,et al.  A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes , 1993, Cell.

[127]  A. Ichinose,et al.  Two genetic defects in a patient with complete deficiency of the b-subunit for coagulation factor XIII. , 1993, Blood.

[128]  J. Penney,et al.  Homozygotes for Huntington's disease , 1987, Nature.

[129]  D. Rifkin,et al.  Requirement for transglutaminase in the activation of latent transforming growth factor-beta in bovine endothelial cells , 1993, The Journal of cell biology.

[130]  M. Motoki,et al.  Transglutaminase-induced cross-linking between subdomain 2 of G-actin and the 636-642 lysine-rich loop of myosin subfragment 1. , 1998, Biophysical journal.

[131]  Y. Suzuki,et al.  Elastase inhibitor elafin is a new type of proteinase inhibitor which has a transglutaminase-mediated anchoring sequence termed "cementoin". , 1994, Journal of biochemistry.

[132]  L. Fésüs.  Transglutaminase-Catalyzed Protein Cross-Linking in the Molecular Program of Apoptosis and Its Relationship to Neuronal Processes , 1998 .

[133]  G. Johnson,et al.  Tissue Transglutaminase Is an In Situ Substrate of Calpain: Regulation of Activity , 1998, Journal of neurochemistry.

[134]  L. Golbe,et al.  Prevalence and natural history of progressive supranuclear palsy , 1988, Neurology.

[135]  M. Zern,et al.  A role for tissue transglutaminase in hepatic injury and fibrogenesis, and its regulation by NF-kappaB. , 1997, The American journal of physiology.

[136]  S. Snyder,et al.  Increased apoptosis of Huntington disease lymphoblasts associated with repeat length-dependent mitochondrial depolarization , 1999, Nature Medicine.

[137]  D. Fuchs,et al.  Degradation of tryptophan in neurodegenerative disorders. , 1999, Advances in experimental medicine and biology.

[138]  A. Delacourte,et al.  Alzheimer's disease: Tau proteins, the promoting factors of microtubule assembly, are major components of paired helical filaments , 1986, Journal of the Neurological Sciences.

[139]  T. Peters,et al.  Human jejunal transglutaminase: demonstration of activity, enzyme kinetics and substrate specificity with special relation to gliadin and coeliac disease. , 1985, Clinical science.

[140]  T. Ternynck,et al.  Natural autoantibodies are involved in the haemolytic anaemia of NZB mice. , 1994, Journal of autoimmunity.

[141]  G. Johnson,et al.  Modulation of the in Situ Activity of Tissue Transglutaminase by Calcium and GTP* , 1998, The Journal of Biological Chemistry.

[142]  P M Steinert,et al.  A novel function for transglutaminase 1: attachment of long-chain omega-hydroxyceramides to involucrin by ester bond formation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[143]  G. Melino,et al.  Transglutaminase 1 Mutations in Lamellar Ichthyosis , 1998, The Journal of Biological Chemistry.

[144]  J. Uitto,et al.  The α5 Chain of Type IV Collagen Is the Target of IgG Autoantibodies in a Novel Autoimmune Disease with Subepidermal Blisters and Renal Insufficiency* , 2000, The Journal of Biological Chemistry.

[145]  K. Oka,et al.  Internal Ca2+ mobilization is altered in fibroblasts from patients with Alzheimer disease. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[146]  T. Rapoport,et al.  A novel pathway for secretory proteins? , 1990, Trends in biochemical sciences.

[147]  E. Thorsby,et al.  Identification of a putative motif for binding of peptides to HLA-DQ2. , 1996, International immunology.

[148]  A. Hackam,et al.  Inhibiting Caspase Cleavage of Huntingtin Reduces Toxicity and Aggregate Formation in Neuronal and Nonneuronal Cells* , 2000, The Journal of Biological Chemistry.

[149]  E. Savilahti,et al.  Human α‐lactalbumin and bovine β‐lactoglobulin absorption in infants , 1994 .

[150]  C. Catassi,et al.  Coeliac disease in the year 2000: exploring the iceberg , 1994, The Lancet.

[151]  K. Yoneda,et al.  Expression of transglutaminase 1 in human epidermis. , 1995, The Journal of investigative dermatology.

[152]  D. Appelt,et al.  The association of tissue transglutaminase with human recombinant tau results in the formation of insoluble filamentous structures , 1997, Brain Research.

[153]  M. Gorny,et al.  CSF antibodies to myelin basic protein and to myelin‐associated glycoprotein in multiple sclerosis. Evidence of the intrathecal production of antibodies , 1983, Acta neurologica Scandinavica.

[154]  J. Vincent,et al.  The unstable trinucleotide repeat story of major psychosis. , 2000, American journal of medical genetics.

[155]  D. Mosher,et al.  Assembly of Fibronectin into Extracellular Matrix , 1991 .

[156]  B. Hyman,et al.  Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[157]  E. Bonifacio,et al.  Antibodies to tissue transglutaminase C in Type I diabetes , 1999, Diabetologia.

[158]  D. Neill,et al.  Aggregates from mutant and wild‐type α‐synuclein proteins and NAC peptide induce apoptotic cell death in human neuroblastoma cells by formation of β‐sheet and amyloid‐like filaments , 1998, FEBS letters.

[159]  E. Thorsby,et al.  HLA restriction patterns of gliadin- and astrovirus-specific CD4+ T cells isolated in parallel from the small intestine of celiac disease patients. , 1998, Tissue antigens.

[160]  M N Marsh,et al.  Gluten, major histocompatibility complex, and the small intestine. A molecular and immunobiologic approach to the spectrum of gluten sensitivity ('celiac sprue'). , 1992, Gastroenterology.

[161]  L. Franco,et al.  Core Histones Are Glutaminyl Substrates for Tissue Transglutaminase* , 1996, The Journal of Biological Chemistry.

[162]  P. Steinert,et al.  The structure of the transglutaminase 1 enzyme. Deletion cloning reveals domains that regulate its specific activity and substrate specificity. , 1994, The Journal of biological chemistry.

[163]  P. Lymberi,et al.  Increased natural autoantibody activity to cytoskeleton proteins in sera from patients with necrobiosis lipoidica, with or without insulin-dependent diabetes mellitus. , 1995, Autoimmunity.

[164]  C. Miller,et al.  Transglutaminase and the Neuronal Cytoskeleton in Alzheimer's Disease , 1986, Journal of neurochemistry.

[165]  M. L. Schmidt,et al.  α-Synuclein in Lewy bodies , 1997, Nature.

[166]  G. Forloni,et al.  α‐Synuclein and Parkinson's disease: Selective neurodegenerative effect of α‐synuclein fragment on dopaminergic neurons in vitro and in vivo , 2000 .

[167]  M. Beal.  Mitochondria, free radicals, and neurodegeneration , 1996, Current Opinion in Neurobiology.

[168]  K. Arima,et al.  Immunoelectron-microscopic demonstration of NACP/α-synuclein-epitopes on the filamentous component of Lewy bodies in Parkinson's disease and in dementia with Lewy bodies , 1998, Brain Research.

[169]  S. Bale,et al.  Splice-site mutation in TGM1 in congenital recessive ichthyosis in American families: molecular, genetic, genealogic, and clinical studies , 2000, Human Genetics.

[170]  W. Franklin,et al.  Differentiation and programmed cell death-related intermediate biomarkers for the development of non-small cell lung cancer: a pilot study. , 1998, Human pathology.

[171]  M. Dalakas,et al.  A New Approach to the Classification of Idiopathic Inflammatory Myopathy: Myositis‐Specific Autoantibodies Define Useful Homogeneous Patient Groups , 1991, Medicine.

[172]  L. Fugger,et al.  Tissue transglutaminase selectively modifies gliadin peptides that are recognized by gut-derived T cells in celiac disease , 1998, Nature Medicine.

[173]  D. Price,et al.  Transglutaminase aggregates huntingtin into nonamyloidogenic polymers, and its enzymatic activity increases in Huntington's disease brain nuclei. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[174]  M. Hayden,et al.  Huntingtin is required for normal hematopoiesis. , 2000, Human molecular genetics.

[175]  G. Canonica,et al.  Evidence of T-lymphocyte functional impairment in Huntington's disease. , 1986, Clinical immunology and immunopathology.

[176]  P. Chan,et al.  Transient Formation of Superoxide Radicals in Polyunsaturated Fatty Acid‐Induced Brain Swelling , 1980, Journal of neurochemistry.

[177]  J. Partanen,et al.  Celiac disease risk in the USA: high prevalence of antiendomysium antibodies in healthy blood donors. , 1998, Scandinavian journal of gastroenterology.

[178]  J. Trojanowski,et al.  A68: a major subunit of paired helical filaments and derivatized forms of normal Tau. , 1991, Science.

[179]  B. Hudson,et al.  The Goodpasture Autoantigen , 2000, The Journal of Biological Chemistry.

[180]  F. Miller,et al.  Lymphocyte activation markers in idiopathic myositis: changes with disease activity and differences among clinical and autoantibody subgroups , 1990, Clinical and experimental immunology.

[181]  L. Lue,et al.  Inflammation, A beta deposition, and neurofibrillary tangle formation as correlates of Alzheimer's disease neurodegeneration. , 1996, Journal of neuropathology and experimental neurology.

[182]  M. Beal.  Huntington's disease, energy, and excitotoxicity , 1994, Neurobiology of Aging.

[183]  L. Toral-Barza,et al.  Calcium stores in cultured fibroblasts and their changes with Alzheimer's disease. , 1996, Biochimica et biophysica acta.

[184]  G. Nepom,et al.  HLA-DQB1 codon 57 is critical for peptide binding and recognition , 1996, The Journal of experimental medicine.

[185]  John X. Morris,et al.  Is Alzheimer's disease inevitable with age?: Lessons from clinicopathologic studies of healthy aging and very mild alzheimer's disease. , 1999, The Journal of clinical investigation.

[186]  L. Haynes,et al.  Stabilization of collagen-tailed acetycholinesterase in muscle cells through extracellular anhorage by transglutaminase-catalysed cross-linking , 2004, Molecular and Cellular Biochemistry.

[187]  M. Rewers,et al.  One third of HLA DQ2 homozygous patients with type 1 diabetes express celiac disease-associated transglutaminase autoantibodies. , 1999, Journal of autoimmunity.

[188]  G. Gerken,et al.  Actin is a target antigen of anti-neutrophil cytoplasmic antibodies (ANCA) in autoimmune hepatitis type-1. , 1997, Journal of hepatology.

[189]  L. K. Rasmussen,et al.  Identification of glutamine and lysine residues in Alzheimer amyloid βA4 peptide responsible for transglutaminase‐catalysed homopolymerization and cross‐linking to α2M receptor , 1994, FEBS letters.

[190]  Roepstorff,et al.  Identification of a Gliadin T‐Cell Epitope in Coeliac Disease: General Importance of Gliadin Deamidation for Intestinal T‐Cell Recognition , 1998, Scandinavian journal of immunology.

[191]  V. Meininger,et al.  Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? , 2000, Archives of dermatology.

[192]  G. Johnson,et al.  Impaired Mitochondrial Function Results in Increased Tissue Transglutaminase Activity In Situ , 2000, Journal of neurochemistry.

[193]  M. Ponec,et al.  Mutations of keratinocyte transglutaminase in lamellar ichthyosis , 1995, Science.

[194]  R. Kannagi,et al.  Calpain activates two transglutaminases from porcine skin , 2004, Archives of Dermatological Research.

[195]  Soo-Youl Kim,et al.  Calpain inhibitors reduce the cornified cell envelope formation by inhibiting proteolytic processing of transglutaminase 1 , 1998, Experimental & Molecular Medicine.

[196]  S. Younkin,et al.  Biochemical detection of Aβ isoforms: implications for pathogenesis, diagnosis, and treatment of Alzheimer’s disease , 2000 .

[197]  T. Ternynck,et al.  Characterization of autoantibody activities in sera anti‐DNA antibody and circulating immune complexes from 12 systemic lupus erythematosus patients , 1996, Journal of clinical laboratory analysis.

[198]  J. Troncoso,et al.  Transglutaminase‐Induced Cross‐Linking of Tau Proteins in Progressive Supranuclear Palsy , 2000, Journal of neuropathology and experimental neurology.

[199]  R. Albin,et al.  Alternative excitotoxic hypotheses , 1992, Neurology.

[200]  G. Melino,et al.  `Tissue' transglutaminase in cell death: a downstream or a multifunctional upstream effector? , 1998, FEBS letters.

[201]  G. Kopen,et al.  Localization of transglutaminase in hippocampal neurons: implications for Alzheimer's disease. , 1996, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[202]  B. Festoff,et al.  Cross‐linking of β‐amyloid protein precursor catalysed by tissue transglutaminase , 1994 .

[203]  S. Bale,et al.  Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis , 1995, Nature Genetics.

[204]  M. Motoki,et al.  Primary structure of microbial transglutaminase from Streptoverticillium sp. strain s-8112. , 1993, The Journal of biological chemistry.

[205]  H. Fuchsbauer,et al.  Bacterial pro-transglutaminase from Streptoverticillium mobaraense--purification, characterisation and sequence of the zymogen. , 1998, European journal of biochemistry.

[206]  J. Brandt,et al.  Trinucleotide repeat length and clinical progression in Huntington's disease , 1996, Neurology.